Hosted on MSN1d
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
FierceBiotech2d
Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials
Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...
Aardvark Therapeutics Announces Pricing of Initial Public Offering
Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets are acting as joint book running managers for the offering.
usaherald1d
Aardvark Lands $94M IPO as Biotech Wave Gains Momentum
Aardvark Therapeutics Inc. made its public market debut Thursday, securing $94 million in its initial public offering (IPO).
Green Bay wine lounge to close after 7 years of business. Here's what we know | Streetwise
Aardvark Wine Lounge, 304 Pine St., in Green Bay opened Jan. 6, 2017 and will officially close on Feb. 21, according to a ...
Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments
Aardvark Therapeutics plans a $100M IPO for metabolic treatments, targeting rare Prader-Willi syndrome with a potential ...
FierceBiotech8d
CF-focused Sionna goes public in $135M IPO, while Aardvark plots $103M listing
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...
BioWorld2d
Aardvark stock sinks first day; IPO to fund obesity drugs
Raising $94.2 million in gross proceeds, Aardvark Therapeutics Inc. became the fifth biopharma company to list on Nasdaq so far in 2025.